Do We Need Radiotherapy in Grade II Ependymoma?

Aleksandra Napieralska*, Wojciech Majewski and Leszek Miszczyk

Radiotherapy Department, Maria Sklodowska-Curie National Research Institute of Oncology Gliwice Branch, Gliwice, Poland

Purpose/Objectives: The debate on whether radiotherapy (RT) is an essential part of primary treatment in patients with grade II ependymoma (G2E) is still ongoing, and this study aimed to evaluate its role.

Materials/Methods: A retrospective analysis of all the consecutive patients treated due to G2E in years 1985–2019 was performed. The group consisted of 116 patients with a small predominance of woman (55% vs. 45%) and the location of the tumor in the brain (58% vs. 42%). All had surgery as the primary treatment with 47% R0 resection. Radical RT was applied in 81 patients. In majority of cases (91%), patients received local irradiation.

Results: Median follow-up was 65 months, and during that time, 17 patients died. Five- and 10-year overall survival (OS) of the whole group was 87% and 83%. Radical surgery (R0 vs. R1/2) improved OS ($p = 0.004$), but the difference was observed only in patients with brain lesions ($p = 0.01$). Five- and 10-year progression-free survival (PFS) was 68% and 51%, respectively. Looking at the treatment of recurrence, those who received RT as a part of the treatment of the recurrent tumor had better OS ($p = 0.048$)—5- and 10-year OS of 85% and 78% vs. 66% and 57%. In the multivariate analysis, radical surgery (R0 vs. R1/2) and the use of RT in the primary treatment improved PFS ($p = 0.006$ and 0.007). Based on the location of the tumor, the positive influence of RT on PFS was observed only in the case of patients with brain tumors ($p = 0.01$). Also, comparing R1/2 surgery with R0 resection—the benefit of RT was only observed in R1/2 group (0.02).

Conclusions: RT in the case of patients with G2E is a valuable treatment of the recurrent disease. Patients with brain lesions after nonradical surgery might benefit from the local irradiation in terms of PFS.

Keywords: ependymoma, brain tumor, adjuvant treatment, radiotherapy, neuro-oncology

INTRODUCTION

Ependymomas are rare central nervous system tumors and represent less than 2% of central nervous system tumors in adults and less than 6% in children (1). The Current National Comprehensive Cancer Network (NCCN) and The European Association of Neuro-Oncology (EANO) guidelines recommend maximal safe resection with adjuvant radiotherapy (RT) or observation for patients with G2 ependymomas (G2E). Local irradiation is advised in case of brain lesions or subtotal
were as follows: “ependymoma”, “radiotherapy”, “grade 2 tumors”, and “grade II ependymoma”. The manual searches of the reference lists of the included studies were used to identify the ones that the electronic search might have failed to identify. Studies included must meet the inclusion criteria: the subtype of G2E according to the WHO classification, the number of patients with G2 tumors if more than one subtype was the topic of the article and the follow-up and information about the outcome, at least part of the patients must have received radiotherapy as part of primary treatment, the article must be published in English, and full text of the article had to be available.

MATERIAL AND METHODS

A retrospective analysis of patients treated in years 1985-2019 due to ependymoma was performed. Study inclusion criteria were histopathologically confirmed G2E, at least 2 months of follow-up from the date of the diagnosis and an available data concerning delivered radical RT. In all the cases, the diagnosis was based on the radiologic imaging (computed tomography (CT) in earlier years of the study and magnetic resonance (MR) evaluation of the brain or spine) and pathologic examination of the tumor tissue samples. The diagnosis of other brain tumor in the past was not an exclusion criterion if the pathologic examination confirmed different histopathology of a tumor and no brain irradiation had been performed. The study was approved by the hospital ethical committee and performed in accordance with the Helsinki Declaration.

The survival and local control rates were the primary endpoints of the analysis. Overall survival (OS) was calculated from the date of the diagnosis of the tumor to the date of death or the date of the last follow-up visit. Progression-free survival (PFS) was calculated from the date of the diagnosis of the tumor to the date of documented progression (local or distant—based on diagnostic imaging) of the tumor or the date of death of the patient. Eastern Cooperative Oncology Group (ECOG) scale was used to classify patients’ performance status. In statistical analysis, OS and PFS were calculated using Kaplan–Meier method. The missing dates of deaths were obtained from the Polish National Cancer Registry. Patient’s outcomes were divided into 4 categories: alive with no evidence of disease (NED); alive with disease (AWD); dead of concurrent/intercurrent disease (DOC); and dead of unknown cause (DUC). Median follow-up was estimated by the Kaplan–Meier analysis with the reversed meaning of the status indicator. Various patients’ characteristics were included in the univariate and multivariate analyses to identify their impact on OS and PFS. The comparisons were made with the use of the log-rank test and Cox-regression model. Variables with p-value of <0.05 in the log-rank test and univariate Cox analysis were used in the multivariate Cox analysis. The comparison of characteristics of patients in RT and no-RT group was performed with Student’s t- and Chi-2 tests. A p-value of ≤0.05 was regarded as being statistically significant. Statistical analysis was performed using Statistica software (version 12.0).

The literature review was performed using PubMed and included all articles published from 1996 to 2020. Terms used for search were “ependymoma”, “radiotherapy”, “grade 2 tumors”, and “grade II ependymoma”. The manual searches of the reference lists of the included studies were used to identify the ones that the electronic search might have failed to identify. Studies included must meet the inclusion criteria: the subtype of G2E according to the WHO classification, the number of patients with G2 tumors if more than one subtype was the topic of the article and the follow-up and information about the outcome, at least part of the patients must have received radiotherapy as part of primary treatment, the article must be published in English, and full text of the article had to be available.

RESULTS

Patient’s Characteristics

During the study period, 244 patients with ependymoma were identified in the hospital database and 116 had histopathological diagnosis of G2E and met study inclusion criteria. Two independent pathological evaluations of tissue samples were conducted in 43 patients (37%). Among others: 19 (16%) had specimens evaluated in medical university pathology department, 9 (8%) had evaluation in forensic department, 6 (5%) in neuropathology department, and 6 (5%) more had evaluation carried in neurosurgical hospital outside our region. Remaining 29% had tissues evaluated in pathology departments, mainly in our region, but the name of the institution which performed the evaluation was unavailable. Information about Ki67 index was available in 27 patients, and it ranged from 1% to 100% (median 1%). The patients’ and treatment characteristics are presented in Table 1. The comparison of RT and no-RT group is presented in Table 2. The most common symptoms in patients with cranial tumors were local pain (61%), visual deficits/dizziness (42%), vomiting/nausea (36%), and consciousness disturbances/faint (24%). Frequently reported symptoms among those with spinal lesions were local pain (71%), paresis (35%), and paresthesia (29%). The diagnosis was based on imaging—MR with or without CT was performed in 80% of the patients and 20% had solely CT.

Primary Treatment—Surgery

Surgery was the primary treatment modality in all of the patients. Mean preoperative tumor dimensions were 3.9 × 2.5 × 2.3 cm (SD ± 2.7 × 1.6 × 1.3 cm). The extent of the resection (EOR) was determined by radiologist based on the postoperative imaging (CT or MR performed 24 to 48 h after the surgery). However, operative notes were also used to assess EOR, especially if imaging was not available. EOR was designated as either a subtotal resection [STR, which included biopsy only, gross residual determined by a neurosurgeon, or residual enhancement on postoperative imaging, meaning macroscopically but not microscopically radical resection (R1) and macroscopically not-radical resection (R2)] or gross total resection [GTR, defined as a complete resection determined by the neurosurgeon and/or radiologist, meaning macro- and microscopically radical resection of the tumor (R0)]. Fifty-five patients (47%) had GTR confirmed...
The second and third surgeries were performed in 14 and 2 patients, respectively. During the next surgery, a higher-grade (G3) tumors were found in 4 patients (in 3 children and 1 adult). Chemotherapy (CTH) was part of the primary treatment in 6 cases. All patients who received CTH were children and in 3 of them anaplastic ependymoma was found during the second surgery. In Poland, majority of pediatric oncologic centers apply CTH according to the national protocols and all children included into the study were treated in accordance with the same national protocol. The systemic agents used were as follows: etoposide 150 mg/m² (days 1–3 and 42–44) and ifosfamide 3 g/m² (days 1–3, 21–23, 42–44, and 63–65). All children received 4 cycles of CTH after the surgery and before the adjuvant RT. Two of them were previously diagnosed with other brain tumor: one with xanthoastrocytoma 3 years earlier and the other one with a meningioma 1 year earlier. Among the adults, one patient was a survivor of breast cancer and one was diagnosed with neurofibromatosis type 2 and had malignant peripheral nerve sheath tumor of the optic nerve. During the follow-up, one patient was diagnosed with skin melanoma and died due to the progression of this disease. Two more patients were diagnosed with asymptomatic meningiomas within the irradiation field.

### Primary Treatment—Radiotherapy

Radical RT was part of the primary treatment in 81 cases (70%). In 8 patients, information regarding irradiation technique was unavailable. Among the other 73 patients, 9 were treated with old radiotherapy techniques (2D/Cobalt), 17 had 3D conformal radiotherapy (3D CRT), and 47 was irradiated with new techniques—19 with VMAT, 26 with IMRT, and 2 with TomoTherapy. A thermoplastic mask was used for treatment position reproducibility. The clinical target volume (CTV) and

### TABLE 1 | Patients’ and treatment characteristics.

| Characteristic | Value |
|----------------|-------|
| Age at diagnosis | Median 35, Range (SD) 2-82 (± 17.9) |
| Children | 15 (13%) |
| Adults | 101 (87%) |
| Sex | Female 64 (55%), Male 52 (45%) |
| ECOG performance status | 0: 29 (25%), 1: 76 (66%), 2: 8 (7%), No data: 3 (2%) |
| Primary site | Brain: 67 (58%), Supratentorial: 22 (19%), Infratentorial: 45 (39%), Spinal cord: 49 (42%) |
| Dissemination at diagnosis | Yes: 9 (8%), No: 107 (92%) |
| Underwent surgery | Yes: 116 (100%), Total (R0): 55 (47%), Subtotal (R1 or R2/biopsy): 55 (47%), No data: 6 (6%) |
| Underwent radiotherapy in primary treatment | Yes: 81 (70%), No: 35 (30%) |
| Underwent chemotherapy in primary treatment | Yes: 6 (6%), No: 110 (94%) |

ECOG, Eastern Cooperative Oncology Group; R0, radical resection (macro- and microscopically); R1, macroscopically radical resection (but not microscopically); R2, macroscopically nonradical resection.

### TABLE 2 | Patients’ characteristic in radiotherapy (RT) and no-radiotherapy (no-RT) group.

| Characteristic | RT | No-RT | p-value |
|----------------|----|-------|---------|
| Age (mean)     | 36.3 | 36.4 | 0.977 |
| Gender         |     |       | 0.594 |
| Male           | 43% | 49% |
| Female         | 57% | 51% |
| ECOG performance status |     |       | 0.320 |
| 0              | 28% | 21% |
| 1              | 63% | 76% |
| 2              | 9%  | 3%  |
| Primary site   |     |       | 0.748 |
| Brain          | 57% | 60% |
| Spine          | 43% | 40% |
| Dissemination at diagnosis |     |       | 0.331 |
| Yes            | 6%  | 11% |
| No             | 94% | 89% |
| Surgery        |     |       | 0.147 |
| R0             | 49% | 52% |
| R1/R2          | 51% | 48% |
| MRI in diagnosis |     |       | 0.168 |
| Yes            | 83% | 71% |
| No             | 17% | 29% |

ECOG, Eastern Cooperative Oncology Group; MRI, magnetic resonance imaging; RT, radical resection (macro- and microscopically); R0, radical resection (macro- and microscopically); R1, macroscopically radical resection (but not microscopically); R2, macroscopically nonradical resection.
normal structures have been defined on CT with MRI fusion for the patients treated since introduction of Eclipse planning system in year 2003. Among those who were irradiated with 3D CRT or dynamic techniques, 13 had treatment planning based only on CT and in 51 patients MRI was used to improve delineation process. The gross tumor volume (GTV) included the operative bed and the residual tumor as defined by contrast-enhanced T1-weighted, T2-weighted, and fluid-attenuated inversion recovery (FLAIR) sequences. In pre-MR era, preoperative and postoperative contrast-enhanced tumor visible on CT was considered GTV. Seventy-two patients had local irradiation and the CTV covered tumor bed in 46 patients, residual tumor with tumor bed in 19 patients, ventricular system with tumor bed in 2 patients, and part of involved spinal canal with additional margin in 5 patients. An additional geometric expansion (usually 5–7 mm) was added to the abovementioned CTV to create the planning target volume (PTV) to account for setup errors and intrafraction motion. CranioSpinal Irradiation (CSI) was applied in 7 patients. Characteristics of the doses and fields used in primary treatment are presented in Table 3. In two patients, data concerning the field and fractionation were not available due to the changes in the treatment planning system. RT was delivered with protons in two patients and with the use of 6–23 MV photon beams in all the others. In the case of patients who received CSI, the total dose (TD) of 30.6–36 Gy (median 36) was delivered to craniospinal axis. One patient did not completed RT due to the deterioration of performance status and finished the irradiation after the total dose of 43.2 Gy. Primary treatment applied in all of the patients is presented on Figure 1.

Recurrence Treatment

The recurrence of the disease was observed in 34 patients (29%) after median time of 61 months (range 1–407 months). All but 7 patients received some form of local treatment (surgery or RT) of recurrent lesions. Characteristics of RT applied in recurrence treatment are presented in Table 3. The effect of this RT was evaluated in 13 cases with stagnation of the tumor observed in 12 of them and partial regression in one. Total number of patients who received second and third courses of RT was 13 and 1, respectively. Metastases were diagnosed in 8 patients during the follow-up with spinal canal as the most common location of the dissemination (in 6 of them).

Overall Survival

Median follow-up was 65 months, and during that time, 17 patients died. Five- and 10-year OS of the whole group was 87% and 83%. Patients with brain lesions had 5- and 10-year OS of 84% and 77% compared with 5- and 10-year OS of 93% and 93% for patients with spinal tumors. At the end of follow-up, 10 patients are DOC, 7 DUC, 31 AWD, and 68 NED. Patients younger than 30 years old (p = 0.08) and those with the spinal location of the tumor (p = 0.08) tended to live longer. Only GTR improved OS (p = 0.004) with 5- and 10-year OS of 97% and 97% vs. 81% and 74%, respectively, for GTR vs. STR. Looking at the location of the tumor, the difference between GTR and STR was observed only in patients with brain lesions (p = 0.01) with no difference in patients with spinal tumors (p = 0.51). Patients with cranial tumors and R0 resection had 10-year OS of 100% compared with 10-year OS of 68% for patients with no radical surgery. CTH or RT did not influence survival of the whole group, and what is more, RT, applied in the case of STR, did not improved OS. What is interesting is that patients who presented with pain had better OS compared with those with no such primary symptom of the disease (p = 0.02). Looking at the treatment of recurrence, those who received RT as part of the treatment of the recurrent tumor had better OS (p = 0.048)—5- and 10-year OS of 85% and 78% vs. 66% and 57% for patients without irradiation in recurrence treatment, respectively.

Progression-Free Survival

Median PFS was 65 months, and during that time, local, local and distant, and distant recurrence was diagnosed in 34, 7, and 4 patients, respectively. Five- and 10-year PFS of the whole group was 68% and 51%. Patients with brain lesions had 5- and 10-year PFS of 63% and 45% compared with 5- and 10-year PFS of 78% and 62% for patients with spinal tumors. The univariate analysis confirmed that results with p = 0.025. EOR (GTR vs. STR, p = 0.001) and use of RT in the primary treatment (p = 0.003) had positive influence on PFS in the univariate analysis. The presence of nausea/vomiting had negative impact on PFS (p = 0.03). Also, patients with brain lesions and presence of paresis had worse PFS (p = 0.03). The multivariate analysis confirmed the impact of EOR and RT on improved PFS (p = 0.006 and 0.007). Positive influence of RT on PFS was observed only in the case of patients with brain tumors (p = 0.01, Figure 2); however, the number of events was very small in patients with spinal tumors. Also, comparing those who had STR with GTR—the benefit of RT was observed in the STR group (p = 0.02, Figures 3 and 4).

DISCUSSION

According to the WHO 2016 classification, central nervous system ependymal tumors can be classified as subependymomas (WHO

| TABLE 3 | Radiotherapy characteristics. |
| --- | --- | --- | --- | --- | --- | --- |
| Group | Number of pts | TD (range) (Gy) | Median TD (Gy) | fd (range) (Gy) | Median fd (Gy) | Local irradiation/craniospinal/ND |
| Primary treatment | | | | | | |
| Brain tumors | 46 | 45.0–60.0 | 54.0 | 1.6–2.0 | 1.8 | 40/5/– |
| Spinal tumors | 35 | 41.4–56.0 | 45.0 | 1.6–2.0 | 1.8 | 32/2/– |
| Recurrence treatment | | | | | | |
| Brain tumors | 17 | 7.0–54.0 | 18.0 | 1.5–18.0 | 5.5 | 11/6/– |
| Spinal tumors | 3 | 30.0–45.0 | 37.5 | 1.8–1.9 | 1.8 | 2/0/1 |

fd, fraction dose; Gy, grey; ND, no data; pts, patients; RT, radiotherapy; TD, total dose.
G1), myxopapillary ependymomas (WHO G1), ependymomas (WHO G2), ependymomas RELA fusion-positive (WHO G2 or G3), or anaplastic ependymomas (WHO G3) (44). Treatment of ependymomas is one of the most controversial issues in neurooncology. EANO guidelines, based on the current WHO classification divided patients into nine subgroups based on anatomical location (supratentorial, posterior fossa, spinal) and patient age. Distinct genetic and epigenetic alterations had been identified, and distinct outcomes for each group were reported. Such findings may lead to more a precise diagnostic and prognostic evaluation, therapies dedicated to molecular subgroup (like the one led by Merchant TE), and in the future, new recommendations (3, 26). As a consequence of very low incidence of adult ependymomas, there is a lack of prospective clinical trials in this population and most of the reported series on these neoplasms are retrospective or include limited number of patients (3, 5, 7, 10–43, 45) (Tables 3 and 4). Only several prospective studies were conducted in the pediatric population which all concluded that RT should be part of the treatment (26).

**Cranial Ependymomas**

Adult ependymomas are rare tumors that still generate controversy with regard to their clinical management (2, 3, 6, 47). Surgery plays an important role, and many authors reported that EOR impacts the outcome. However, GTR can be hindered by anatomical factors, such as adherence of the tumor to the nearby organs. Reoperation following initial incomplete surgery or at tumor recurrence is advocated, assuming that GTR could be achievable. However, surgery alone especially in the case of STR, is rarely curative and the vast majority of relapses are local (6, 11, 12, 14–20, 22, 23, 25–27, 30, 42, 43, 45, 46). What is interesting is that a few authors have found no correlation between the EOR and the prognosis, suggesting that in some cases, less-aggressive approach combined with an adjuvant irradiation can provide similar outcome as GTR (10, 27, 28). The positive influence of EOR on survival was observed in our study, and those who had GTR of the tumor presented the best outcome (Figure 2). Radical resection, confirmed with postoperative MR is advocated for all patients suitable for such surgery.

Among other factors found to positively influence OS were younger age with cutoff value within the range of 30–55 years and such correlation was also observed in our study (4, 6, 10, 13, 16, 27, 42, 46). Only Vera-Bolanos et al. reported that patients younger than 44 years old had worse PFS compared with the older ones, but in her study, spinal and cranial tumors were mixed, and patients with tumors of other than G2 were included (43). Another factor identified in many studies as associated with worse survival prognosis was the supratentorial location of the lesion (6, 10, 13, 15, 20, 24, 43, 46). In contrast, Aizer et al. found that patients with supratentorial tumors are having the better outcome. Based on their analysis and literature review of studies delaying RT in the case of completely resected supratentorial tumors, they suggested that irradiation could be reserved in case of recurrent lesions with part of the patients avoiding radiation-induced brain toxicity (11, 16, 24). Their observations regarding the location impact were not confirmed by any other author. We did not find the correlation between the supra- and infratentorial tumors and survival in our study.

The role of RT is one of the most debatable issues in terms of G2E treatment. The influence of RT in case of GTR in cranial tumors was not confirmed by several authors (4, 10, 13–15, 18, 24). In our study, no benefit from RT after GTR in terms of OS or
FIGURE 2 | Survival curves based on the use of radiotherapy (RT) in primary treatment with the regard to tumor location: overall survival (A) and progression-free survival (B) of patients with spinal location of the tumor based on the use of RT in primary treatment and overall survival (C) and progression-free survival (D) of patients with brain location of the tumor based on the use of RT in primary treatment.

FIGURE 3 | Progression-free survival of patients with STR (R1 or R2 resection) of the tumor based on the use of RT in primary treatment (p = 0.02).
FIGURE 4 | Progression-free survival of patients with GTR (R0 resection) of the tumor based on the use of RT in primary treatment ($p = 0.29$).

TABLE 4 | Studies of patients with cranial grade II ependymomas with regard on the impact of adjuvant radiotherapy.

| In favor of adjuvant radiotherapy | Against adjuvant radiotherapy |
|-----------------------------------|------------------------------|
| Reni M et al. (42) 51 adults:     | Dutzmann et al. (10) 64 adults (33 G II): |
| 10-year OS: 59% vs. 68%—RT vs. no RT; | 10-year OS: 90% vs. 82%—RT vs. no RT |
| 10-year FFS: 34% vs. 12%—RT vs. no RT |     |
| Metellus et al. (6) 114 adults:  |     |
| 10-year OS: 87% vs. 78%—RT vs. no RT |     |
| Snider et al. (12) 482 children ≤3-year olds (302 G II); |     |
| SEER database: |     |
| 10-year OS: 50% vs. 43%—RT vs. no RT |     |
| Guyotat et al. (14) 88 adults (66 G II); |     |
| 10-year OS: 86% vs. 77%—RT vs. no RT; 10-year PFS: 75% vs. 50%—RT vs. no RT |     |
| Metellus et al. (16) 152 adults (109 G II): |     |
| 10-year PFS: 75% vs. 45%—RT vs. no RT |     |
| Rodriguez et al. (18) 2,408 pts (2,132 spine and brain G II); |     |
| SEER database: |     |
| not reported OS/PFS with respect to RT |     |
| Woo Wee et al. (19) 172 adults (106 G II): |     |
| 10-year PFS and OS: 54% and 82% vs. 41% and 80%—RT vs. no RT |     |
| Ernestus et al. (21) 67 children (58 G II): |     |
| not reported OS/PFS with respect to RT |     |
| Cage et al. (23) literature review: 182 children (115 GII): |     |
| 5-year OS: 87% vs. 73%—GTR + RT vs. GTR |     |
| Perilongo et al. (25): 92 children (81 GII): |     |
| 10-year OS and PFS: 58% and 41% vs. 52% and 20%—RT vs no RT (whole group) |     |
| Merchant et al. (26) 356 children (215 GII), ACNS0121 study: |     |
| 10-year EFS and OS: 69% and 82% vs. 33% and 49%—RT vs. delayed/no RT |     |
| Rogers L et al. (27): 45 pts (43 low G): |     |
| 5-year LC: 100% vs. 75%—RT vs. no RT; 10-year OS: 67% vs. 43%—GTR + RT vs. GTR |     |
| (Continued) |     |
| Wang et al. (17) 55 patients (17 G II); supratentorial extraventricular tumors: not reported OS/PFS with respect to RT |     |
| Prabhu et al. (4) 1,787 adults (1,471 G II); NCDB: |     |
| 5-year OS: 82% vs. 88%—RT vs. no RT |     |
| Korshunov et al. (20) 258 pts (131 low G): |     |
| 5-year OS: 95% vs. 96%—RT vs. no RT |     |
| Wang et al. (22) 30 pts (17 G II) + literature review of 106 pts (68 G II): |     |
| 10-year OS and PFS: 95% and 80%—RT and no RT |     |
| Alon et al. (24) 26 children (23 GII): |     |
| 10-year OS and PFS: 65% and 60% vs. 72% and 58%—RT vs. no RT (posterior fossa tumors); 10-year OS and PFS: 67% and 58% vs. 44% and 40%—RT vs. no RT (supratentorial tumors) |     |
| Vera-Bolanos et al. (43) 282 adults (212 spine and brain G II): |     |
| 10-year PFS: 75% vs. 58%—GTR vs. GTR + RT; 10-year PFS: 58% vs. 50%—STR vs. STR + RT |     |
| Amirian et al. (46) 367 pts (348 GII spine and brain); SEER analysis: not reported OS/PFS with respect to RT |     |
PFS was observed, although vast majority of those patients received irradiation. There is a possibility that delaying RT in such patient population could be considered in highly selected cases. However, the absolute benefit of adjuvant RT in adult group has not been validated via prospective randomized trial, and there is no ongoing trial as well, so its value can only be examined based on the available retrospective data to date (26). Our analysis of patients after STR showed that this group could benefit from postoperative RT in terms of PFS which was also observed by other authors (6, 14, 16, 19, 47–49). This thesis, to administer adjuvant RT to patients after STR of intracranial G2E is also supported by EANO and NCCN consensus guidelines (2, 3). However, there is no concrete evidence as to which therapeutic strategy is optimal, especially with regard to the time point and extent or RT (48). Concepts regarding target volume for RT changed over the years. In the past, patients with ependymoma often received whole brain RT or CSI. Since several studies demonstrated that local irradiation is sufficient to achieve good results, the treatment fields shrink to cover only the local extent of the disease (tumor/tumor bed with additional margin of 1–2 cm), so with no evidence of dissemination, local RT to total dose of 54–59.4 Gy is advocated (3, 26, 48, 49). The CSI is reserved for cases with dissemination diagnosed based on MR or the cerebrospinal fluid analysis. There is also a possibility to consider a boost to tumor bed and any gross disease after the dose of 54 Gy in cases with lesions located in a close proximity of organs at risk (49).

The role of CTH either before or following RT remains uncertain. Recurrent ependymoma remains a challenge without a uniformly accepted approach. Some patients undergo an additional course of RT, which as shown in our study, could provide better survival (3, 49). Conventional or

### TABLE 4 | Continued

| In favor of adjuvant radiotherapy | Against adjuvant radiotherapy |
|----------------------------------|-----------------------------|
| Pejavar S et al. (28) 39 children (19 G II): 10-year PFS and OS: 36% and 68% vs. 0% and 61%—RT vs. no RT (whole group) |  |
| Ernestus et al. (29) 126 pts (87 G II): 5-year PFS: 76% vs. 48%—RT vs. no RT |  |
| Deng et al. (30) 632 children: 5-year OS and CSS: 71% vs. 62% and 73% vs. 67%—RT vs. no RT |  |

On the left studies in favor of adjuvant radiotherapy, on the right against postoperative irradiation (4, 6, 10–30, 42, 43, 49).

CSS, cancer-specific survival; EFS, event-free survival; FFS, failure-free survival; G, grade; GTR, gross total resection; LC, local control; NCDB, National Cancer Database; NTR, near-total resection; OS, overall survival; PFS, progression-free survival; pts, patients; RT, radiotherapy; SEER, the Surveillance, Epidemiology and End Results; STR, subtotal resection; vs., versus.

### TABLE 5 | Studies of patients with spinal grade II ependymomas with regard on the impact of adjuvant radiotherapy.

| In favor of adjuvant radiotherapy | Against adjuvant radiotherapy |
|----------------------------------|-----------------------------|
| Oh et al. (31) 348 adults (337 G II); literature review: 5- and 10-year PFS: 98% and 98% vs. 65% and 50%—GTR vs. STR + RT vs. STR | Wang et al. (32) 636 adults (621 G II); SEER database: not reported OS/PFS with respect to RT |
| Rodriguez et al. (18) 2,408 pts (2,132 spine and brain G II); SEER database: not reported OS/PFS with respect to RT | Roldan Urgoiti et al. (15) 139 pts (106 brain and spine G II): not reported OS/PFS with respect to RT |
| Savoor et al. (33) 69 adults (42 G II): 10-year PFS and LC: 77% and 86% vs. 68% and 50%—SRT + RT vs. SRT | Tarapore et al. (34) 134 pts (101 G II): 10-year PFS: 98% vs. 70% vs. 82%—GTR vs. STR + RT vs. STR |
| Gomez et al. (35) 37 pts (26 low G other than myxopapillary): not reported OS/PFS with respect to RT | Brown et al. (36) 1058 pts (1019 G II); NCD analysis: 5-year OS—96% vs. 95%—RT vs. no RT |
| Zou et al. (36) literature review of 13 children: not reported OS/PFS with respect to RT | Sun et al. (37) literature review of 138 pts: not reported OS/PFS with respect to RT |
| Lin et al. (38) 20 pts (13 G II): 10-year LC and OS: 100% and 100%—GTR and STR + RT | Lin et al. (39) 64 children; SEER database: 10y OS: 87% vs. 75%—RT vs. no RT |
| Lee et al. (45) 19 pts: 5-year LC and OS: 100% and 100%—GTR and STR + RT | Lee et al. (40) 88 pts (61 G II): 10-year DFS: 55% vs. 90%—RT vs. no RT (whole group) |

On the left studies in favor of adjuvant radiotherapy, on the right against postoperative irradiation (7, 15, 18, 31–41, 43, 45, 46).

DFS, disease-free survival; G, grade; GTR, gross total resection; LC, local control; OS, overall survival; PFS, progression-free survival; pts, patients; RT, radiotherapy; SEER, the Surveillance, Epidemiology and End Results; STR, subtotal resection; vs., versus.
hypofractionated stereotactic irradiation photon therapy as well as protons could provide satisfactory local results (3). Whenever possible, repeated surgery is also advocated (2, 3). Long-term follow-up with MR is recommended for all the patients, regardless of the EOR.

Spinal Ependymomas

Patients with spinal cord ependymomas have better prognosis than with other intramedullary glial tumors or brain-located ependymomas (43, 46, 49). However, factors affecting prognosis have not been clearly defined for this population and simple extrapolation from studies on intracranial ependymomas is not valid (31, 34). The management of spinal ependymomas typically begins with surgery, which offers removal of mass effect and can achieve oncologic control in some patients (3, 33). The postoperative MR confirming GTR is strongly recommended. Similarly to patients with brain lesions, EOR was also found as the most important factor influencing survival (3, 8, 31–35, 40, 41, 43, 46) (Table 5). The goal of GTR must be balanced against the risk of aggressive surgery, which depending on the lesion location can cause severe neurologic deficits. Complications following spinal tumor resection include motor and sensory loss, bowel and bladder dysfunction, and cerebrospinal fluid leaks (34).

Based on the best available and most recent data, the NCCN and EANO guidelines recommend adjuvant RT following STR of G2E (2, 3). Several reports showed that adjuvant irradiation could significantly improve local control, especially in patients where GTR was not performed (31, 33, 35, 36, 45). Authors concluded that although adjuvant RT may not ultimately affect OS, decreasing recurrence can appreciably benefit the patient outcomes by avoiding repeated surgeries, which are associated with significant morbidities (31, 33). RT is typically targeted to the spinal level of disease (GTV) with a margin accounting for microscopic spread (CTV) and intra- and infrafraction motion (PTV). The craniospinal irradiation is reserved for cases with dissemination diagnosed based on MR or cerebrospinal fluid analysis with possible boost on gross visible disease. Taking into account the tolerance dose of 45–50 Gy for spinal cord tissues and the studies which did not show an improvement in the outcome after the application of higher doses, the irradiation to the total dose of 45–50.4 Gy with a fraction dose of 1.5–1.8 Gy is recommended (higher doses are used in case of tumors in the spinal canal in regions of the nerve roots and the cauda equina below the spinal cord) as providing satisfactory results (2, 3, 31, 33, 35, 38, 47, 49, 50). In contrast to those findings but in accordance with other researchers, we did not find adjuvant RT as influencing survival (8, 32, 34, 37, 40, 46). However, it is worth mentioning that vast majority of our patients, similarly to the study by Lin et al., received RT even in case of GTR, so it is hard to advise not to irradiate (39). This also reflects how hard is the clinical decision-making process of selecting patients suitable for radiation, which makes one of the drawbacks of retrospective studies since the goal is not to verify the best solution but to cure the patient. Similar to our results were observed by Gomez et al., and they still advise to administer adjuvant RT in case of STR or biopsy (35). Sun et al. in their literature review included cases in which adjuvant RT was used only in 27% of patients and authors concluded that adjuvant treatment did not prevent from tumor recurrence and those who received irradiation had worse PFS. It is worth mentioning that indication for adjuvant treatment were not analyzed with regard to the EOR in that study (37). Lee et al. did not report the outcome with regard to the tumor grade which could have influenced the observed differences (40). What is more, among studies against RT, there are four which analyzed SEER or NCDB data. As shown in the study by Metelius et al. in which over 40% cases were misclassified, national database evaluations could raise concerns about proper histopathological diagnosis (8, 16, 32, 39, 46). What is important, while the use of RT remains controversial, the modern planning techniques have increased precision of targeting, decreasing the effects on surrounding tissue and the risk of possible complications. Because recurrences can occur many years after the treatment, regardless of the EOR, long-term follow-up with MR is recommended. Older age, male sex, other than classical G2 pathological types (cellular, papillary, giant cell types) were found as negatively influencing the outcome (8, 32, 37, 39, 41).

Study Limitations

There are several limitations of our study. Foremost, the retrospective nature of this study hampers the value of our findings. The other is the long duration of time during which patients were eligible for inclusion and lack of molecular testing which is now a pathologic standard in case of neurooncologic lesions. What is more, we did not perform the review of the pathologic diagnosis for the purpose of this study, but since our cancer center lacks neurosurgery department and patients had surgery in many different hospitals all over the region, we were not able to collect the tissue samples and evaluate them due to logistic reasons. As the study period covered very long time—from 1985 to 2019, some of those specimens are no longer available, because according to the Polish medical law, tissues are stored in pathology department for a period of 20 years and then disposed. However, the analysis of pathology department which conducted the pathologic evaluation showed that over 70% had confirmation of very reliable diagnosis. What is more, our findings are strengthened by the relatively large number of cases included, long follow-up, and number of information regarding treatment applied. Last but not least, the general consensus regarding the management of ependymomas has evolved based on the institutional experience and retrospective studies like ours. However, taking into account changes in pathological classification and introduction of molecular subgroups, there is a need for multi-institutional or cooperative group prospective studies or registries to better define these populations and inform future clinical investigations.

CONCLUSIONS

Radiotherapy applied in the case of patients with G2 ependymoma is a valuable treatment of recurrent disease. Patients with brain lesions after nonradical surgery might benefit from local irradiation in terms of progression-free survival. The low number of events in
patients with spinal tumors does not allow for an unequivocal conclusion regarding the role of RT. Also, the role of irradiation after radical resection remains debatable. RT as part of the treatment of recurrence has positive impact on overall survival.

DATA AVAILABILITY STATEMENT

The original contributions presented in the study are included in the article/supplementary material. Further inquiries can be directed to the corresponding author.

ETHICS STATEMENT

The studies involving human participants were reviewed and approved by The Institutional Review Board committee in MSC National Research Institute of Oncology in Gliwice (number: KB/430-05/20). Written informed consent for participation was not required for this study in accordance with the national legislation and the institutional requirements.

AUTHOR CONTRIBUTIONS

Conceptualization: AN. Methodology: AN. Software: AN. Validation: AN. Formal analysis: AN. Investigation: AN. Resources: AN. Data curation: AN. Writing—original draft preparation: AN and LM. Writing—review and editing: AN, LM, and WM. Visualization: AN. Supervision: LM and WM. Project administration: AN. All authors have read and agreed to the published version of the manuscript.

REFERENCES

1. Ostrom QT, Cioffi G, Gittleman H, Patil N, Waite K, Kruchko C, et al. CBTRUS Statistical Report: Primary Brain and Other Central Nervous System Tumors Diagnosed in the United States in 2012-2016. Neuro Oncol (2019) 21:v1–v100. doi: 10.1093/neuonc/noz150
2. Nccn.org. National Comprehensive Cancer Network, National Comprehensive Cancer Network Clinical Practice Guidelines in Oncology: Central Nervous System Cancers. Version 1 (2021) (Accessed 2 July 2021).
3. Rudá R, Reifenberger G, Froppaz D, Pfister SM, Laprie A, Santarius T, et al. EANO Guidelines for the Diagnosis and Treatment of Epithelial Tumors. Neuro Oncol (2018) 20:445–56. doi: 10.1093/neuonc/nox166
4. Prabhu RS, Coma CD, Ward MC, Heimerling JH, Dhakal R, Buchwald ZS, et al. The Effect of Adjuvant Radiotherapy on Overall Survival in Adults With Intracranial Ependymoma. Neurooncol Pract (2020) 7:391–9. doi: 10.1093/ noop/npa070
5. Franceschi E, Froppaz D, Rudá R, Hau P, Preusser M, Houllier C, et al. EURACAN Domain. Rare Primary Central Nervous System Tumors in Adults: An Overview. Front Oncol (2020) 10:996. doi: 10.3389/fonc.2020.00996
6. Metellus P, Guyotat J, Chinot O, Durand A, Barrie M, Giorgi R, et al. Adult Intracranial WHO Grade II Ependymomas: Long-Term Outcome and Prognostic Factor Analysis in a Series of 114 Patients. Neuro Oncol (2010) 12:976–84. doi: 10.1093/neuonc/noq047
7. Elsamadicy AA, Koo AB, David WB, Lee V, Zogg CK, Kundishora AJ, et al. Comparison of Epidemiology, Treatments, and Outcomes in Pediatric Versus Adult Ependymoma. Neurooncol Adv (2020) 2:vdaa019. doi: 10.1093/noajnl/vdaa019
8. Brown DA, Goyal A, Takami H, Graffe CS, Mahajan A, Krauss WE, et al. Radiotherapy in Addition to Surgical Resection may Not Improve Overall Survival in WHO Grade II Spinal Ependymomas. Clin Neuro Neurosurg (2020) 189:105632. doi: 10.1016/j.clineuro.2019.105632
9. Yebob DN, Liao K-P, Guadagnolo BA, Rao G, Bishop A, Chung C, et al. National Patterns of Care in the Management of World Health Organization Grade II and III Spinal Ependymomas. World Neurosurg (2019)24:51878–8750. doi: 10.1016/j.wneuro.2018.12.159
10. Dützmann S, Schatlo B, Lobrinus A, Murek M, Wostrack M, Weiss C, et al. A Multi-Center Retrospective Analysis of Treatment Effects and Quality of Life in Adult Patients With Cranial Ependymomas. J Neurooncol (2013) 114:319–27. doi: 10.1007/s11060-013-1187-2
11. Aizer AA, Ancukiewicz M, Nguyen PL, Macdonald SM, Yock TI, Tarbell NJ, et al. Natural History and Role of Radiation in Patients With Supratentorial and Infratentorial WHO Grade II Ependymomas: Results From a Population-Based Study. J Neurooncol (2013) 115:411–9. doi: 10.1007/s11060-013-1237-9
12. Snider CA, Yang K, Mack SC, Suh JH, Chao ST, Merchant TE, et al. Impact of Radiation Therapy and Extent of Resection for Ependymoma in Young Children: A Population-Based Study. Pediatr Blood Cancer (2018) 65: e26880. doi: 10.1002/pbc.26880
13. Nuo M, Yu JJ, Varshneya K, Alexander J, Mukherjee D, Black KL, et al. Treatment and Survival of Supratentorial and Posterior Fossa Ependymomas in Adults. J Clin Neurosci (2016) 28:24–30. doi: 10.1016/j.jocn.2015.11.014
14. Guyotat J, Metellus P, Giorgi R, Barrie M, Jouvet A, Fevre-Montange M, et al. Infratentorial Ependymomas: Prognostic Factors and Outcome Analysis in a Multi-Center Retrospective Series of 106 Adult Patients. Acta Neurochir (Wien) (2009) 151:947–60. doi: 10.1007/s00701-009-0417-z
15. Roldán Urgoiti GB, Singh AD, Tsang R, Noldal RA, Lim G, Chan JA, et al. Population Based Analysis Ependymoma Patients in Alberta From 1975 to 2007. Can J Neurol Sci (2014) 41:742–7. doi: 10.1017/cjn.2014.107
16. Melletus P, Barrie M, Figarella-Branger D, Chinot O, Giorgi R, Gouvernet J, et al. Multicentric French Study on Adult Intracranial Ependymomas: Prognostic Factors Analysis and Therapeutic Considerations From a Cohort of 152 Patients. Brain (2007) 130:1338–49. doi: 10.1093/brain/awn406
17. Wang M, Zhang R, Liu X, Li D, Qiu C, Zhao P, et al. Supratentorial Extraventricular Ependymomas: A Retrospective Study Focused on Long-Term Outcomes and Prognostic Factors. Clin Neuro Neurosurg (2018) 165:1–6. doi: 10.1016/j.clineuro.2017.12.013
18. Rodríguez D, Cheung MC, Housri N, Quinones-Hinojosa A, Camphausen K, Koniaris LG. Outcomes of Malignant CNS Ependymomas: An Examination of 2408 Cases Through the Surveillance, Epidemiology, and End Results (SEER) Database (1973-2005). J Surg Res (2009) 156:340–51. doi: 10.1016/j.jss.2009.04.024
19. Woo Wee C, Kim IH, Park C-K, Lim DH, Nam D-H, Yoon HI, et al. Postoperative Radiotherapy for WHO Grade II-III Intracranial Ependymoma in Adults: An Intergroup Collaborative Study (KROG 18-06/KNOG 18-01). Radiother Oncol (2020) 150:4–11. doi: 10.1016/j.radonc.2020.05.045
20. Korshunov A, Golanov A, Sycheva R, Timirgaz V. The Histologic Grade is a Prognostic Factor Analysis in a Series of 114 Patients. Neuro Oncol (2020) 7:391–9. doi: 10.1093/neuonc/noo166
21. Ernestus RI, Schröder R, Stützer H, Klug N. Prognostic Relevance of Localization and Grading in Intracranial Ependymomas of Childhood. Childs Nerv Syst (1996) 12:522. doi: 10.1007/BF00261604
22. Wang Q, Cheng J, Li J, Zhang S, Liu W, Ju Y, et al. The Survival and Prognostic Factors of Supratentorial Cortical Ependymomas: A Retrospective Cohort Study and Literature-Based Analysis. Front Oncol (2020) 10:1585. doi: 10.3389/fonc.2020.101585
23. Cage TA, Clark AJ, Aranda D, Gupta N, Sun PP, Parsa AT, et al. A Systematic Review of Treatment Outcomes in Pediatric Patients With Intracranial Ependymomas. J Neurosurg Pediatr (2013) 11:673–81. doi: 10.3171/2013.2. PEDS12345
24. Alton T, Dunham C, Carret A-S, Tabori U, Meneely PD, Zelcer S, et al. The Role of Resection Alone in Select Children With Intracranial Ependymoma: The Canadian Pediatric Brain Tumour Consortium Experience. Childs Nerv Syst (2015) 31:57–65. doi: 10.1007/s00381-014-2575-4

25. Perilongo G, Massimino M, Sotti G, Belfontali T, Masiero L, Rigobello L, et al. Analyses of Prognostic Factors in a Retrospective Review of 92 Children With Ependymoma: Italian Pediatric Neuro-Oncology Group. Med Pediatr Oncol (1997) 29:79–85. doi: 10.1002/(sici)1096-911x(199708)29:2<79::aid-mpo3>3.0.co;2-o

26. Merchant TE, Bendel AE, Sabin ND, Burger PC, Shaw DW, Chang E, et al. Conformal Radiation Therapy for Pediatric Ependymoma, Chemotherapy for Incompletely Resected Ependymoma, and Observation for Completely Resected, Supratentorial Ependymoma. J Clin Oncol (2019) 37:974–83. doi: 10.1200/JCO.18.01765

27. Rogers L, Puschel J, Sptetzel R, Shapiro W, Coons S, Thomas T, et al. Is Gross-Total Resection Sufficient Treatment for Posterior Fossa Ependymomas? J Neurosurg (2005) 102:629–36. doi: 10.3171/jns.2005.102.6.0629

28. Pejarar S, Polley M-Y, Rosenberg-Wohl S, Chennupati S, Prados MD, Berger MS, et al. Pediatric Intracranial Ependymoma: The Roles of Surgery, Radiation and Chemotherapy. J Neurooncol (2012) 106:367–75. doi: 10.1007/s11060-011-0671-9

29. Ernestus R, Schröder R, Stützer H, Klug N. The Clinical and Prognostic Relevance of Grading in Intracranial Ependymomas. Br J Neurosurg (1997) 11:421–8. doi: 10.1080/0268869974592592

30. Deng X, Lin D, Yu L, Xu Z, Zhang N, Zhou H, et al. The Role of Postoperative Radiotherapy in Pediatric Patients With Grade II Intracranial Ependymomas: A Population-Based, Propensity Score-Matched Study. Cancer Manag Res (2018) 10:5151–24. doi: 10.2147/CMAR.S181900

31. Oh MC, Ivan ME, Sun MZ, Kaur G, Safaei M, Kim JM, et al. Adjuvant Radiotherapy Delays Recurrence Following Subtotal Resection of Spinal Cord Ependymomas. Neuro Oncol (2013) 15:08–215. doi: 10.1093/neuonc/noon286

32. Wang C, Yuan X, Zuo J. Individualized Prediction of Overall Survival for Primary Intramedullary Spinal Cord Grade II/III Ependymoma. World Neurosurg (2020) 143:e149–56. doi: 10.1016/j.wneuro.2020.07.049

33. Savoor R, Sita TI, Dahdaleh NS, Helenowski I, Kalapurakal JA, Marymont MH, et al. Long-Term Outcomes of Spinal Ependymomas: An Institutional Experience of More than 60 Cases. J Neurooncol (2021) 151:241–7. doi: 10.1007/s11060-020-03658-7

34. Tarapore PE, Modera P, Naujokas A, Oh MC, Amin B, Tihan T, et al. Pathology of Spinal Ependymomas: An Institutional Experience Over 25 Years in 134 Patients. Neurosurgery (2013) 73:247–253; discussion 253. doi: 10.1227/01.neu.0000430764.02973.76

35. Gomez DR, Missett BT, Wara WM, Prados MD, Chang S, et al. High Failure Rate in Spinal Ependymomas With Long-Term Follow-Up. Neuro Oncol (2005) 7:254–9. doi: 10.1215/S115285170001231

36. Zou Y, Xiao Bai H, Wang Z, Jiang Y, Yang L. Radiation Therapy After Subtotal Resection of Pediatric Grade II/III Spinal Ependymomas: What is the Evidence? Childs Nerv Syst (2015) 31:1021–2. doi: 10.1007/s00381-015-2643-4

37. Sun X-Y, Kong C, Lu S-B, Sun S-Y, Guo M-C, Ding J-Z. Survival Outcomes and Prognostic Factors of Patients With Intramedullary Grade II Ependymomas After Surgical Treatments. J Clin Neurosci (2018) 57:136–42. doi: 10.1016/j.jocn.2018.08.001

38. Lin Y-H, Huang C-I, Wong T-T, Chen M-H, Shiu C-Y, Wang L-W, et al. Treatment of Spinal Cord Ependymomas by Surgery With or Without Postoperative Radiotherapy. J Neurooncol (2005) 71:205–10. doi: 10.1007/s11060-004-1386-y

39. Lin Y, Andrew Jea A, Mellkonian SC, Lam S. Treatment of Pediatric Grade II Spinal Ependymomas: A Population-Based Study. J Neurosurg Pediatr (2015) 15:243–9. doi: 10.3171/2014.9.PEDS1477

40. Lee S-H, Chung CK, Kim CH, Kong C, Sun S-Y, Guo M-C, et al. Long-Term Outcomes of Surgical Resection With or Without Adjuvant Radiation Therapy for Treatment of Spinal Ependymoma: A Retrospective Multicenter Study by the Korea Spinal Oncology Research Group. Neuro Oncol (2013) 15:921–9. doi: 10.1093/neuroonc/not038

41. Wang Y, Cai R, Wang R, Yoon SH, Hyun S-J, Kim K-J, et al. Outcome Predictors in the Management of Intradural Classic Ependymoma: An Integrative Survival Analysis. Med (Baltimore) (2018) 97:e10870. doi: 10.1097/MD.0000000000010870

42. Reni M, Brandes AA, Vavassori V, Carallo G, Casagrande F, Vastola F, et al. A Multicenter Study of the Prognosis and Treatment of Adult Brain Ependymal Tumors. Cancer (2004) 100:1221–9. doi: 10.1002/cncr.20074

43. Vera-Bolanos E, Aldape K, Yuan Y, Wu J, Wani K, Neceisto-Reyes MJ, et al. CERN Foundation Clinical Course and Progression-Free Survival of Adult Intracranial and Spinal Ependymoma Patients. Neuro Oncol (2015) 17:440–7. doi: 10.1093/neuroonc/nou162

44. Louis DN, Perry A, Reifenberger G, von Deimling A, Figarella-Branger D, Cavenee WK, et al. The 2016 World Health Organization Classification of Tumors of the Central Nervous System: A Summary. Acta Neuropathol (2016) 131:803–20. doi: 10.1007/s00401-016-1545-1

45. Lee TT, Gromelski EB, Green BA. Surgical Treatment of Spinal Ependymoma and Post-Operative Radiotherapy. Acta Neurochir (Wien) (1998) 140:309–13. doi: 10.1007/s007010050103

46. Amiran SE, Armstrong TS, Gilbert MR, Scheurer ME. Predictors of Survival Among Older Adults With Ependymoma. J Neurooncol (2012) 107:183–9. doi: 10.1007/s11060-011-0730-2

47. Reni M, Gatta G, Mazza E, Vecht C. Ependymoma. Crit Rev Oncol Hematol (2007) 63:81–9. doi: 10.1016/j.critrevonc.2007.03.004

48. Combs SE, Kelter V, Welzel T, Behnisch W, Kulozek A, Bischof M, et al. Influence of Radiotherapy Treatment Concept on the Outcome of Patients With Localized Ependymomas. Int J Radiat Oncol Biol Phys (2008) 71:972–8. doi: 10.1016/j.ijrobp.2007.12.036

49. Schild SE, Nisi K, Scheithauer BW, Wong WW, Lyons MK, Schomberg PJ, et al. The Results of Radiotherapy for Ependymomas: The Mayo Clinic Experience. Int J Radiat Oncol Biol Phys (1998) 42:953–8. doi: 10.1016/s0360-3016(98)00350-2

50. Bentzen SM, Constine LS, Deasy JO, Eisbruch A, Jackson A, Marks LB, et al. Multicenter Study of the Prognosis and Treatment of Adult Brain Ependymal Tumors. Multicenter Study by the Korea Spinal Oncology Research Group. Acta Neuropathol (2015) 17:421–8. doi: 10.1007/s00401-015-1754-1

Conflict of Interest: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Publisher’s Note: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.